Phase I trials for PD-1 targets in EBV-associated malignancies, phase II trials for CD19+ leukemia and lymphoma, relapsed or refractory leukemia and lymphoma, and advanced esophageal cancer are just a few of the numerous clinical trials that are now being conducted (Table 3). This evidence concerns the gene PDCD1 and leukemia.